Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma - Trial NCT06079164
Access comprehensive clinical trial information for NCT06079164 through Pure Global AI's free database. This Phase 1 trial is sponsored by Kite, A Gilead Company and is currently Recruiting. The study focuses on Relapsed/Refractory Large B-cell Lymphoma. Target enrollment is 39 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Kite, A Gilead Company
Gilead Sciences
Timeline & Enrollment
Phase 1
Nov 09, 2023
Dec 01, 2027
Primary Outcome
Phase 1a: Percentage of Participants Experiencing any Dose-limiting Toxicities (DLTs),Phase 1b: Complete Remission (CR) Rate
Summary
This study will have two Phases: Phase 1a and Phase 1b. The goal of Phase 1a of this clinical
 study is to learn more about the safety, tolerability and dosing of study drug KITE-197, in
 participants with relapsed or refractory large B-cell lymphoma (r/rLBCL). The goal of Phase
 1b of this clinical study is learn about the effectiveness of the recommended dose of
 KITE-197 in participants with r/r LBCL.
 
 The primary objectives of this study are:
 
 Phase 1a: To evaluate the safety of KITE-197 in participants with r/r LBCL and determine the
 target dose level for Phase 1b.
 
 Phase 1b: To evaluate the efficacy of KITE-197 in participants with r/r LBCL as measured by
 the complete remission (CR) rate.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06079164
Non-Device Trial